Latest Daily News

More Stories

July 23, 2018

CAR T-cell immunotherapy earned the title “Advance of the Year” in the ASCO Clinical Cancer Advances 2018 annual report.

Read more
June 14, 2018

Combination therapy with the oral BCL-2 inhibitor venetoclax plus a hypomethylating agent demonstrated a tolerable safety profile in elderly patients with untreated acute myeloid leukemia (AML) who were ineligible for standard induction chemotherapy.

Read more
June 4, 2018

Poster Sessions on June 4 gave an in-depth look at data from the KEYNOTE-183 and KEYNOTE-185 trials, which were halted nearly a year ago due to increased risk of death for patients with multiple myeloma who were being treated with the drug combination.

Read more

June 4, 2018

Treatment with the anti-CD19 CAR T-cell therapy axicabtagene ciloleucel (axi-cel) induced durable, high response rates in patients with refractory diffuse large B-cell lymphoma (DLBCL), according to results from the ZUMA-1 trial (Abstract 3003).

Read more

June 4, 2018

CAR T cells offer a valuable new treatment alternative for patients with relapsed/refractory acute lymphoblastic leukemia (ALL) who have exhausted the range of standard therapies.

Read more

June 4, 2018

A chemotherapy-free combination immunotherapy regimen had similar efficacy as the standard chemotherapy regimen in patients with previously untreated, advanced follicular lymphoma in the phase III RELEVANCE trial (Abstract 7500).

Read more

June 4, 2018

Adding nelarabine to chemotherapy improved 4-year disease-free survival (DFS) and provided an overall survival (OS) of 90% in patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL), according to results from the largest phase III clinical trial to date.

Read more

June 2, 2018

Te bb2121 chimeric antigen receptor (CAR) T-cell therapy engineered to target B-cell maturation antigen (BCMA) holds great promise for the treatment of multiple myeloma (MM).

Read more

June 2, 2018

The combination of ibrutinib and rituximab significantly improved progression-free survival (PFS) and response rates compared to placebo plus rituximab in patients with Waldenström’s macroglobulinemia (WM).

Read more

June 2, 2018

Patients with relapsed or refractory multiple myeloma treated with once-weekly carfilzomib had a higher response rate than patients treated with the twice-weekly regimen in the ARROW study, introducing the potential for more convenient dosing for patients.

Read more
June 1, 2018

Saturday InBriefs: Scientific Highlights from ASCO18.

Read more

May 15, 2018

In January, members of an Expert Panel updated ASCO Clinical Practice Guidelines on the role of bone-modifying agents in patients with multiple myeloma.

Read more

May 15, 2018

The StiL NHL1 trial results presented during the 2012 ASCO Annual Meeting Plenary Session (Abstract 3) led to changes in treatment guidelines worldwide for indolent lymphoma.

Read more

May 14, 2018

Hematologic malignancies such as non-Hodgkin lymphoma (NHL) and multiple myeloma are diseases of the elderly with a median age of incidence in the 60s and 70s, respectively.

Read more

May 14, 2018

Immune checkpoints are inhibitory receptors expressed by immune cells that suppress T-cell and other immune cell activation in order to maintain peripheral tolerance and prevent autoimmunity.

Read more

May 11, 2018

Murali Janakiram, MBBS, MD, an assistant professor with Albert Einstein College of Medicine, answers a question posed by an attendee during a Best of ASCO® Meeting.

Read more
June 5, 2017

Results from two separate trials suggest that lenalidomide can induce deeper and longer remission in patients with multiple myeloma when used as part of induction and maintenance therapy.

Read more
June 4, 2017

A planned interim analysis of the OPTIMAL˃60 trial found that a PET-based radiotherapy strategy to treat bulky disease is safe in elderly patients with diffuse large B-cell lymphoma.

Read more
June 4, 2017

Participants discussed 5- and 10-year follow-up data from two separate studies presented during the Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Oral Abstract Session.

Read more

June 2, 2017

Treating multiple myeloma in older patients presents specific challenges and requires certain considerations. 

Read more